It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

All three cannabinoids reduced the electrical activity linked to Nav1.8, but CBG had the strongest effect. This suggests that CBG could be the most promising candidate for developing new pain ...

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.